Baylor College of Medicine
One Baylor Plaza
Houston
Texas
77030
United States
Tel: 713-798-4951
Website: http://www.bcm.tmc.edu/
Email: www@bcm.tmc.edu
196 articles with Baylor College of Medicine
-
Deerfield Management and Baylor College of Medicine Announce Blue Square Discoveries to Advance Novel Therapeutic Treatments
5/17/2021
Deerfield Management Company, a healthcare investment management firm focused on advancing healthcare through investment, information and philanthropy, and Baylor College of Medicine announced a major research collaboration to advance promising therapeutics and support pharmaceutical research and discovery.
-
Athenex, Texas Children’s Cancer Center, and the Center for Cell and Gene Therapy at Baylor College of Medicine Present New Clinical Data on GD2 CAR-NKT Cells in Neuroblastoma at ASGCT Annual Meeting
5/17/2021
Athenex, Inc. announced that investigators from Texas Children’s Cancer Center and the Center for Cell and Gene Therapy at Baylor College of Medicine presented new clinical data from the ongoing GINAKIT2 phase 1 study of Athenex’s cell therapy candidate KUR-501 targeting GD2 in neuroblastoma at the American Society of Gene & Cell Therapy 24th Annual Meeting on Friday, May 14, at 11 am ET.
-
Will We Need COVID-19 Vaccines Every Year? Although the jury is still out, a study out of Charité – Universitätsmedizin Berlin suggests that the answer is yes for a few years, but may be unnecessary after a few years post-pandemic.
-
A current Phase III trial of the Pfizer-BioNTech COVID-19 vaccine has confirmed the protection remains high for at least six months after the second dose. In a statement, Pfizer and BioNTech reported the vaccine was 91.3% effective against the disease.
-
Baylor College of Medicine researchers suggest that the analysis of all protein data from aggressive human cancers could help identify novel treatment targets.
-
Biological E. Limited Starts Phase I/II Clinical Trial of its COVID-19 Vaccine Candidate
11/16/2020
Biological E. Limited, Dynavax Technologies Corporation, and Baylor College of Medicine announced that BE has initiated a Phase I/II clinical trial of its COVID-19 subunit vaccine candidate in India following approval from the Drugs Controller General of India.
-
Harvard Psychiatric Leader Appointed to Posts at Baylor College of Medicine and Menninger Clinic
9/28/2020
Baylor College of Medicine and The Menninger Clinic jointly announce the hiring of Robert J. Boland , M.D., as vice chairman of the Menninger Department of Psychiatry and Behavioral Sciences at Baylor College of Medicine and chief of staff at The Menninger Clinic. Boland joins the organizations on January 4, 2021 , after tran
-
Mymetics Starts Preclinical Studies with Baylor College of Medicine for Virosome-based Covid-19 Vaccine
9/23/2020
Mymetics has started a Covid-19 vaccine development project based on Mymetics' virosome vaccine carrier platform, which will evaluate different rationally designed SARS-CoV-2 antigens for an effective and safe virosome-based Covid-19 vaccine.
-
As we head into cold and flu season, the question arises: Can you get COVID-19 and the flu at the same time?
-
MilliporeSigma and Baylor College of Medicine Collaborate to Advance a Vaccine Manufacturing Platform to Fight Covid-19
5/27/2020
Company will focus on process development and improvements for manufacturing Baylor's Covid-19 vaccine candidates
-
Mymetics and Baylor College of Medicine start Research Collaboration for Virosome-based Covid-19 Vaccines
5/21/2020
Mymetics Corporation announced that its subsidiary, Mymetics BV, has signed a Research Collaboration Agreement with Baylor College of Medicine and Texas Children's Center for Vaccine Development for evaluating their rationally designed recombinant protein-based SARS-CoV and SARS-CoV-2 antigens and combining them with Mymetics' virosomes for the development of a safe and effective Covid-19 vaccine.
-
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
-
AlloVir Expands Its Research Collaboration with Baylor College of Medicine to Discover and Develop Allogeneic, Off-the-Shelf, Virus-Specific T-Cell Therapies for COVID-19
3/23/2020
AlloVir’s proprietary technology is designed to develop virus specific T-cell therapies with potential to treat and prevent several devastating viral diseases with each single cell therapy product
-
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
-
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
-
Marker Therapeutics Reports Interim Results of its MultiTAA T Cell Therapy in Patients with Pancreatic Adenocarcinoma at AACR
7/20/2019
Results show potential of MultiTAA therapy in combination with chemotherapy as a first-line treatment for patients with pancreatic cancer; potential second-line treatment for chemo-refractory patients
-
Here are some of the top research stories that happened around the industry this week.
-
Cell Medica Collaborators, Baylor College of Medicine and Texas Children’s Hospital, Present Preclinical Data for an off-the-shelf CAR-NKT Therapy Platform at American Society of Gene & Cell Therapy 22nd Annual Meeting
5/1/2019
Allogeneic “off the shelf” chimeric antigen receptor-natural killer T cell (CAR-NKT) therapy platform could overcome significant challenges of current autologous CAR-T therapies
-
Tessa Therapeutics, in Collaboration with Baylor College of Medicine, Presents Preclinical Results Showing Enhanced T Cell Responses Against HER2-Positive Solid Tumors Using Novel Combination CAR T Cell Therapy
4/30/2019
Preclinical, 'proof-of-concept' results for a novel 'all-in-one' immunotherapy for the treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-positive solid tumors
-
Cell Medica Collaborator, Baylor College of Medicine, Showcasing Promise of CAR-NKT Therapies at American Society of Gene & Cell Therapy 22nd Annual Meeting
4/17/2019
Collaboration with Baylor College of Medicine and Texas Children’s Hospital includes ground-breaking GINAKIT2 Phase 1 trial